These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15762218)

  • 21. Confluent and reticulated papillomatosis: response to tazarotene.
    Bowman PH; Davis LS
    J Am Acad Dermatol; 2003 May; 48(5 Suppl):S80-1. PubMed ID: 12734485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topical tazarotene 0.05% versus glycolic acid 70% treatment in X-linked ichthyosis due to extensive deletion of the STS gene.
    Cotellessa C; Cuevas-Covarrubias SA; Valeri P; Fargnoli MC; Peris K
    Acta Derm Venereol; 2005; 85(4):346-8. PubMed ID: 16191859
    [No Abstract]   [Full Text] [Related]  

  • 23. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy.
    Draelos ZD; Tanghetti EA;
    Cutis; 2002 Feb; 69(2 Suppl):20-9. PubMed ID: 12095065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topical tazarotene: The BEST (balancing efficacy, speed, and tolerability) in acne trial.
    Shalita A
    Cutis; 2004 Oct; 74(4 Suppl):4-8. PubMed ID: 15543713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A status report on topical tazarotene in the management of acne vulgaris.
    Del Rosso JQ; Tanghetti E
    J Drugs Dermatol; 2013 Mar; 12(3):s53-8. PubMed ID: 23545935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tazarotene foam, 0.1%, for the treatment of acne.
    Smith JA; Narahari S; Hill D; Feldman SR
    Expert Opin Drug Saf; 2016 Jan; 15(1):99-103. PubMed ID: 26560170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Letter: Changes in dermoscopic features in superficial basal cell carcinomas treated with imiquimod.
    Micantonio T; Fargnoli MC; Piccolo D; Peris K
    Dermatol Surg; 2007 Nov; 33(11):1403-5. PubMed ID: 17958603
    [No Abstract]   [Full Text] [Related]  

  • 28. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris.
    Tanghetti E; Dhawan S; Green L; Del Rosso J; Draelos Z; Leyden J; Shalita A; Glaser DA; Grimes P; Webster G; Barnett P; Le Gall N
    J Drugs Dermatol; 2010 May; 9(5):549-58. PubMed ID: 20480800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial.
    Leyden JJ; Tanghetti EA; Miller B; Ung M; Berson D; Lee J
    Cutis; 2002 Feb; 69(2 Suppl):12-9. PubMed ID: 12095064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interactions between tazarotene and ultraviolet light.
    Hecker D; Worsley J; Yueh G; Kuroda K; Lebwohl M
    J Am Acad Dermatol; 1999 Dec; 41(6):927-30. PubMed ID: 10570375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Medication of the month. Tazarotene 0.05%-0.1% (Zorac)].
    Henno A; Hua MT; de la Brassinne M
    Rev Med Liege; 2003 Nov; 58(11):706-8. PubMed ID: 14748200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of tazarotene on ichthyosiform erythroderma of Tay's syndrome.
    Varghese VS; Rai R; Sundaram SV; Prabhu KS; Srinivas CR
    Indian J Dermatol Venereol Leprol; 2007; 73(2):126-7. PubMed ID: 17456926
    [No Abstract]   [Full Text] [Related]  

  • 33. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial.
    Siller G; Rosen R; Freeman M; Welburn P; Katsamas J; Ogbourne SM
    Australas J Dermatol; 2010 May; 51(2):99-105. PubMed ID: 20546215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5% imiquimod cream for the treatment of large superficial basal cell carcinoma.
    Shumack S; Gebauer K; Quirk C; Macdonald K; Walters SA; Owens M
    Arch Dermatol; 2004 Oct; 140(10):1286-7. PubMed ID: 15492202
    [No Abstract]   [Full Text] [Related]  

  • 35. Tazarotene 0.1% cream for the treatment of photodamage.
    Phillips TJ
    Skin Therapy Lett; 2004 Apr; 9(4):1-2. PubMed ID: 15146262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy.
    Tanghetti E; Lebwohl M; Stein Gold L
    J Drugs Dermatol; 2018 Dec; 17(12):1280-1287. PubMed ID: 30586259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks.
    Kang S; Leyden JJ; Lowe NJ; Ortonne JP; Phillips TJ; Weinstein GD; Bhawan J; Lew-Kaya DA; Matsumoto RM; Sefton J; Walker PS; Gibson JR
    Arch Dermatol; 2001 Dec; 137(12):1597-604. PubMed ID: 11735710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of ichthyosiform diseases with topically applied tazarotene: risk of systemic absorption.
    Nguyen V; Cunningham BB; Eichenfield LF; Alió AB; Buka RL
    J Am Acad Dermatol; 2007 Nov; 57(5 Suppl):S123-5. PubMed ID: 17938025
    [No Abstract]   [Full Text] [Related]  

  • 39. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
    Feldman SR; Werner CP; Alió Saenz AB
    J Drugs Dermatol; 2013 Apr; 12(4):438-46. PubMed ID: 23652892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tazarotene gel in childhood Darier disease.
    Micali G; Nasca MR
    Pediatr Dermatol; 1999; 16(3):243-4. PubMed ID: 10383788
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.